Abstract
Thirteen out of 18 young out-patients with simple schizophrenia under neuroleptic treatment completed a double-blind cross-over trial with Madopar® [l-Dopa + benserazid (a peripheral decarboxylase inhibitor)] and placebo. Nine patients were given 900 mg l-Dopa + 225 mg benserazid daily, 1 patient received 600 mg l-Dopa + 150 mg benserazid, and 3 patients, 300 mg l-Dopa + 75 mg benserazid. In these doses, l-Dopa was effective against emotional withdrawal, blunted affect, tendency to isolation and apathy, without inducing or aggravating productive, accessory symptoms. The activity score, according to the specific activity-withdrawal scale, was significantly increased (P<0.05), whereas the total BPRS score (Brief Psychiatric Rating Scale) was slightly, but significantly reduced (P<0.05). In cases where l-Dopa had to be limited to 600 and 300 mg daily, a tendency to anxiety, distortion of thinking, and a sense of unreality were observed, depending on the dose of l-Dopa. In no case were gastrointestinal, cardiovascular or neurological sideeffects observed.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Andén, N.-E., Strömbom, U., Svensson, T.: Dopamine and noradrenaline receptor stimulation: reversal of reserpine-induced suppression. Psychopharmacologia (Berl.) 29, 289–298 (1973)
Angrist, B., Sathananthan, G., Gershon, S.: Behavioural effect of l-Dopa in schizophrenic patients. Psychopharmacologia (Berl.) 31, 1–12 (1973a)
Angrist, B., Sathananthan, G., Wilk, S., Gershon, S.: Behavioural and biochemical effects of l-Dopa in psychiatric patients. In: Frontiers in catecholamine research. 3rd Intern. Catecholamine Symp. Strasbourg-Fr. E. Usdin and S. Snyder, eds., pp. 991–994. Oxford: Pergamon 1973b
Barbeau, A.: l-Dopa therapy in Parkinson's disease: a critial review of nine years' experience. Canad. med. Ass. J. 101, 791–800 (1969)
Barbeau, A.: Dopamine and mental function. In: l-Dopa and behavior, S. Malitz, ed., pp. 9–33. New York: Raven Press 1972
Barbeau, A.: The clinical physiology of side effects in longterm l-Dopa therapy. In: Advances in neurology, vol. 5. Fl. H. McDowell and A. Barbeau, eds., pp. 347–365. New York: Raven Press 1974
Bleuler, E.: Dementia praecox or the group of schizophrenia, pp. 235–239. New York: International Universities Press 1950
Bruno, A., Bruno, S.: Effects of l-Dopa on pharmacological parkinsonism. Acta psychiat. scand. 42, 264–271 (1966)
Celesia, G., Barr, A.: Psychosis and other psychiatric manifestations of levodopa therapy. Arch. Neurol. (Chic.) 23, 1993–2000 (1970)
Cesarec, Z., Eberhard, G., Nordgren, L.: A controlled study of the antipsychotic and sedative effects of neuroleptic drugs and amphetamine in chronic schizophrenics. Acta psychiat. scand. Suppl. 249, 65–77 (1974)
Cotzias, G.: Levodopa in the treatment of Parkinsonism. J. Amer. med. Ass. 218, 1903–1908 (1971)
Delay, J., Deniker, P., Robert, R., Beek, H., Barande, R., Eurieult, M.: Syndromes neurologiques expérimentaux et thérapeutique psychiatrique. I. éffects neurologiques d'un nouveau neuroleptique majeur, le 7843 RP. Press med. 67, 123 (1959)
Duvoisin, R., Yahr, M.: Behavioural abnormalities occurring in Parkinsonism during treatment with l-Dopa. In: l-Dopa and behavior, S. Malitz, ed., pp. 57–72. New York: Raven Press 1972
Ginath, Y., Lavy, S., Abramsky, O., Carmon, A.: Mental complications of l-Dopa therapy in Parkinson's patients. Israel Ann. Psychiat. Related Disciplines 9, 252–264 (1974)
Glasner, S.: The schizophrenias. In: Handbook of psychiatry. P. Solomon and V. Patch, eds., pp. 310–324. Los Altos: Lange Medical Publications 1969
Goodwin, F.: Psychiatric side effects of levodopa in man. J. Amer. med. Ass. 218, 1915–1920 (1971)
Inanaga, K., Tanaka, M.: Effects of l-Dopa on schizophrenia. In: Psychopharmacology, sexual disorders and drug, T. A. Ban, J. R. Boissier, G. J. Gessa, H. Heimann, L. Hollister, H. E. Lehmann, I. Munkvad, H. Steiberg, F. Sulser, A. Sundwall, and O. Vinar, eds., pp. 229–233. Amsterdam-London: North-Holland and Prague: Avicenum, Czechoslovak Medical Press 1973
Klawans, H., Goetz, C., Westheimer, R.: Pathophysiology of schizophrenia and the striatum. Dis. nerv. Syst. 33, 711–719 (1972)
Langelier, P., Roberge, A., Boucher, R., Poirier, L.: Effects of chronically administered l-Dopa in normal and lesioned cats. J. Pharmacol. exp. Ther. 187, 15–26 (1973)
Marsden, C., Dolphin, A., Duvoisin, R., Jenner, P., Tarsy, D.: Role of noradrenaline in levodopa reversal of reserpine akinesia. Brain Res. 77, 521–525 (1974)
Murphy, D., Henry, G., Weingartner, H.: Catecholamines and memory: Enhanced verbal learning during l-Dopa administration. Psychopharmacologia (Berl.) 27, 319–326 (1972)
MØller Nielsen, I.: Pharmacological vs. clinical physiognomy of neuroleptics, with special reference to their sedative and antipsychotic effects. In: Clinical physiognomy of thioxanthenes. Acta psychiat. belg. 74, 473–484 (1974)
MØller Nielsen, I., Christensen, A. V.: Long term effects of neuroleptics drugs. J. Pharmacol. 5, Suppl. 2, 68 (1974)
Overall, J., Gorham, D.: The brief psychiatric rating scale. Psychol. Rep. 10, 799–812 (1962)
Randrup, A., Munkvad, I.: Evidence indicating an association between schizophrenia and dopaminergic hyperactivity in the brain. Orthomolecular Psychiat. 1, 2–7 (1972)
Riklan, M.: l-Dopa and Parkinsonism. A psychological assessment. Springfield, Ill.: Thomas 1973
Stevens, J.: An anatomy of schizophrenia? Arch. gen. Psychiat. 29, 177–189 (1973)
Svensson, R., Waldeck, B.: On the role of catecholamines in motor activity: Experiments with inhibitors of synthesis and of monoamine oxidase. Psychopharmacologia (Berl.) 18, 357–365 (1970)
Venables, P.: A short scale for rating “activity-withdrawal” in schizophrenics. J. ment. Sci. 103, 197–199 (1957)
Yaryura-Tobias, J., Diamon, B., Merlis, S.: The action of l-Dopa on schizophrenic patients (a preliminary report). Curr. ther. Res. 12, 528–531 (1970)
Yaryura-Tobias, J., Diamond, B., Merlis, S.: l-Dopa: A psychiatric tool. In: l-Dopa and behavior, S. Malitz, ed., pp. 121–130. New York: Raven Press 1972
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gerlach, J., Lühdorf, K. The effect of l-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs. Psychopharmacologia 44, 105–110 (1975). https://doi.org/10.1007/BF00421193
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00421193